FarmaMondo Group Welcomes Natalie Douglas as New Board Director to Enhance Patient Access Globally
FarmaMondo Group has recently announced the appointment of Natalie Douglas as an Independent Board Director, marking a pivotal step in the company’s growth and commitment to expanding global patient accessibility to life-saving medications. Founded as an international commercial pharmaceutical organization, FarmaMondo collaborates with pharmaceutical and biotechnology firms to deliver innovative and specialty medicines across more than 50 emerging markets.
With over two decades in the pharmaceutical industry, Natalie Douglas is highly respected for her transformative contributions. She is recognized as a pioneer in managed access and commercialization drug programs, now regarded as the industry standard for providing access to essential medicines in international markets. Prior to joining FarmaMondo, Douglas held leadership roles at JJ and later founded IDIS, an international specialty pharmaceutical organization based in Princeton, New Jersey. At IDIS, she revolutionized the concept of managed access programs, successfully implementing over 200 global access initiatives for numerous pharmaceutical and biotech companies focused on rare and serious medical conditions.
Under her guidance, IDIS became the foremost global provider of managed access programs, which caught the attention of Clinigen Group, who later acquired it, underscoring the substantial commercial value of Douglas's innovative approach. She demonstrated that expanded access could be operationally delivered nationwide, adhering to ethical standards while being scalable enough to benefit patients worldwide.
Yaron Spigel, CEO of FarmaMondo, praised Douglas's achievements, stating, "Natalie Douglas is one of the most significant figures in global patient access, credited with developing the industry standard for managed access programs and connecting pharma companies to healthcare facilities in hard-to-reach places around the world." He emphasized that her presence on the board is critical as the company seeks to broaden its partnerships with U.S.-based pharmaceutical and biotech firms wishing to ensure comprehensive global service to patients.
As FarmaMondo continues on its growth trajectory in the U.S. market, the company maintains a diverse portfolio that encompasses over 50 therapies targeting oncology, rare diseases, and specialty care. With 14 regional affiliates spread across multiple nations, FarmaMondo has proven to be at the forefront of delivering innovative solutions to ensure patients receive the care they need. The introduction of Douglas into their leadership team is expected to be instrumental in solidifying these initiatives, especially given her extensive experience and success in scaling such programs.
In a statement, Natalie expressed her excitement about joining FarmaMondo’s board: "It's a privilege to lend my global access expertise to FarmaMondo and help them expand their U.S. market presence. I am impressed with what Yaron and his team have built to drive the future model of international market access. FarmaMondo's collaborative approach with pharma partners resonates with my dedication to assisting patients who desperately require life-changing medicines beyond the conventional reach of major markets."
With its operational model aimed at delivering comprehensive access strategies, FarmaMondo is at an exciting juncture of enhancing its impact on patient care. As the healthcare landscape continually evolves, having leaders like Natalie Douglas who are passionate about improving access to medications will be vital for navigating the challenges ahead. Her addition is not only strategic but also reflects FarmaMondo’s commitment to ensuring that all patients, regardless of geographical barriers, receive the treatments they need.
FarmaMondo Group is dedicated to bridging the gap between pharmaceutical companies and patients by providing a complete, integrated market presence in over 50 emerging markets. Their commitment spans from early access initiatives to full commercialization efforts, ensuring that vital medications reach those who need them most. With a focus on oncology, hematology, endocrinology, neurology, and metabolic diseases, FarmaMondo strives to empower patients globally and support healthcare professionals in their vital work.
With over two decades in the pharmaceutical industry, Natalie Douglas is highly respected for her transformative contributions. She is recognized as a pioneer in managed access and commercialization drug programs, now regarded as the industry standard for providing access to essential medicines in international markets. Prior to joining FarmaMondo, Douglas held leadership roles at JJ and later founded IDIS, an international specialty pharmaceutical organization based in Princeton, New Jersey. At IDIS, she revolutionized the concept of managed access programs, successfully implementing over 200 global access initiatives for numerous pharmaceutical and biotech companies focused on rare and serious medical conditions.
Under her guidance, IDIS became the foremost global provider of managed access programs, which caught the attention of Clinigen Group, who later acquired it, underscoring the substantial commercial value of Douglas's innovative approach. She demonstrated that expanded access could be operationally delivered nationwide, adhering to ethical standards while being scalable enough to benefit patients worldwide.
Yaron Spigel, CEO of FarmaMondo, praised Douglas's achievements, stating, "Natalie Douglas is one of the most significant figures in global patient access, credited with developing the industry standard for managed access programs and connecting pharma companies to healthcare facilities in hard-to-reach places around the world." He emphasized that her presence on the board is critical as the company seeks to broaden its partnerships with U.S.-based pharmaceutical and biotech firms wishing to ensure comprehensive global service to patients.
As FarmaMondo continues on its growth trajectory in the U.S. market, the company maintains a diverse portfolio that encompasses over 50 therapies targeting oncology, rare diseases, and specialty care. With 14 regional affiliates spread across multiple nations, FarmaMondo has proven to be at the forefront of delivering innovative solutions to ensure patients receive the care they need. The introduction of Douglas into their leadership team is expected to be instrumental in solidifying these initiatives, especially given her extensive experience and success in scaling such programs.
In a statement, Natalie expressed her excitement about joining FarmaMondo’s board: "It's a privilege to lend my global access expertise to FarmaMondo and help them expand their U.S. market presence. I am impressed with what Yaron and his team have built to drive the future model of international market access. FarmaMondo's collaborative approach with pharma partners resonates with my dedication to assisting patients who desperately require life-changing medicines beyond the conventional reach of major markets."
With its operational model aimed at delivering comprehensive access strategies, FarmaMondo is at an exciting juncture of enhancing its impact on patient care. As the healthcare landscape continually evolves, having leaders like Natalie Douglas who are passionate about improving access to medications will be vital for navigating the challenges ahead. Her addition is not only strategic but also reflects FarmaMondo’s commitment to ensuring that all patients, regardless of geographical barriers, receive the treatments they need.
About FarmaMondo Group
FarmaMondo Group is dedicated to bridging the gap between pharmaceutical companies and patients by providing a complete, integrated market presence in over 50 emerging markets. Their commitment spans from early access initiatives to full commercialization efforts, ensuring that vital medications reach those who need them most. With a focus on oncology, hematology, endocrinology, neurology, and metabolic diseases, FarmaMondo strives to empower patients globally and support healthcare professionals in their vital work.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.